Skip to content

Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission

Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03494101
Enrollment
40
Registered
2018-04-11
Start date
2018-06-15
Completion date
2020-01-31
Last updated
2018-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Salmonella Infection Non-Typhoid

Brief summary

Stool and blood samples from patients with a non-typhoid Salmonella infection will be collected during an observation period of six months and analyzed for changes in the microbiota diversity and composition, mutation rates in the Salmonella strains and the specific immune response evoked by the infection. Findings are compared to healthy individuals and individuals with acute, infectious diarrhea caused by other microorganisms.

Detailed description

Infection processes of a non-typhoid Salmonella infection in humans are not well understood and so far, only little research has been conducted in this area. Findings from preclinical studies, using mouse models, attributed a fundamental role in infection control to the gut microbiota and the host immune system (antibody response). In mouse models a non-typhoid Salmonella infection provokes a pronounced antibody response and salmonella-inflicted gut inflammation alters the microbiota diversity and composition in the gut lumen. To date there is only scarce evidence on similar effects in humans. During the study, longitudinal stool and blood samples will be collected from patients with a non-typhoid Salmonella infection at different study time points (2 weeks, 4 weeks and 6 months after positive Salmonella stool culture) and analyzed for changes in the microbiota, mutation rates in the Salmonella strains and the specific immune response evoked by the infection (e.g. anti-bodies). At each study time point clinical information will be investigated with a questionnaire to assess current symptoms, medication etc. Findings will be compared to healthy individuals and patients with acute, infectious diarrhea caused by other microorganisms than non-typhoid Salmonella.

Interventions

OTHERBlood samples

Blood samples will be collected and analyzed at different study time points

OTHERStool samples

Stool samples will be collected and analyzed at different study time points

Clinical information will be collected at different study time points using questionnaires

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

General inclusion criteria: * Signed informed consent. * Ability to understand and follow study procedures and understand informed consent * Age 18-75 years. Inclusion criteria for patients with non-typhoid Salmonella infection (n=20) * Acute diarrhea (≥3 bowel movements per day for ≤4 weeks) * Stool cultures positive for non-typhoid Salmonella ≤4 weeks before inclusion Inclusion criteria for patients with acute, infectious diarrhea without non-typhoid Salmonella infection (n=10) * Acute diarrhea (≥3 bowel movements per day for ≤4 weeks) * Stool cultures negative for non-typhoid Salmonella infection within ≤ 4 weeks Inclusion criteria for healthy volunteers (n=10) • No symptoms of acute or chronic diarrhea (2 bowel movements per week to 2 per day)

Exclusion criteria

* Current use of antibiotics * Medication with immunosuppressants (e.g. corticoids, biological therapy). * Major medical/surgical/psychiatric condition requiring ongoing management. Minor well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present. * Major diagnosis known to chronically affect gut microbiota (e.g. inflammatory bowel disease, liver cirrhosis, colon carcinoma, systemic sclerosis). * Current diagnosis of a hematological disorder (e.g. severe anemia with hemoglobin \<7 g/dl, leukemia) or any other absolute contraindication for blood donation. * Participation in other clinical study interfering with study procedures. * Inability to understand study procedures in order to provide inform consent. * Previous participation in the same study.

Design outcomes

Primary

MeasureTime frameDescription
Genomic mutations in non-typhoid Salmonella strains4 weeks after index stool cultureAnalyze the evolution of non-typhoid Salmonella during acute infection and remission in humans. The primary variable of interest is the number of observed genomic mutations in non-typhoid Salmonella strains.

Secondary

MeasureTime frameDescription
Identification of most frequently mutated surface antigenes of non-typhoid Salmonella4 weeks after index stool cultureIdentification of escape mechanisms of non-typhoid Salmonella (i.e. mutation of surface antigens) to avoid specific immune responses (i.e. antibodies) during acute infection and remission.
Gen Cluster Expression2 weeks, 4 weeks and 6 months after index stool cultureIdentification of Salmonella gene clusters expressed during early phases of infection compared to remission.
Mutated non-typhoid Salmonella strains4 weeks and 6 months after index stool cultureQuantification of mutated non-typhoid Salmonella strains that escape specific immune responses.
Microbiota changes2 weeks, 4 weeks and 6 months after index stool cultureComposition (i.e. number of bacteria species identified) and relative diversity of the gut microbial community during acute non-typhoid Salmonella infection and remission. Findings will be compared to changes occurring in the microbiota of healthy individuals and individuals with acute, infectious diarrhea caused by microorganisms other than Salmonella.
Quantification of non-typhoid Salmonella genes associated with: tissue invasion, antibiotic resistance and virulence factors4 weeks after index stool cultureTotal number of Salmonella genes associated with tissue invasion Total number of antibiotic resistance genes Total number of virulence factor genes
Antibody producing B-cell clones4 weeks after index stool cultureNumber of antibody-producing cell clones (and their corresponding antibodies) against non-typhoid Salmonella isolated from peripheral blood B cells of subjects during remission. Measured variable: Number of Salmonella-specific B-cells per ml blood 4 weeks after infection.
Antibody repertoire2 weeks and 4 weeks after index stool cultureIdentification of the antibody repertoire against non-typhoid Salmonella during acute infection in peripheral blood. Measured variable: Antibody titers against various non-typhoid Salmonella strains.
Antigen- Antibody recognition4 weeks and 6 months after index stool cultureNumber of antigens of non-typhoid Salmonella recognized by the antibodies isolated from the previous endpoint.
Development of irritable bowel syndromeEnd of observational period (6 months)Number of patients who develop an irritable bowel syndrome after a non-typhoid Salmonella infection.
Antibody producing cells2 weeks and 4 weeks after index stool cultureComposition (i.e. number of antibody-producing cells) and relative diversity of antibody-producing cells specific for non-typhoid Salmonella.

Countries

Switzerland

Contacts

Primary ContactBenjamin Misselwitz, PD Dr.med.
benjamin.misselwitz@usz.ch+41 44 255 1111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026